Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: A preferential survivin-cyclin B link

Leukemia

Volumn 16, Issue 4, 2002, Pages 726-735

  Kuttler, F ^a   Valnet Rabier, M B ^a   Angonin, R ^a   Ferrand, C ^a   Deconinck, E ^a   Mougin, C ^a   Cahn, J Y ^a   Fest, T ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Cyclin B; Diffuse large B cell lymphoma; Survivin

Indexed keywords

ANTIMITOTIC AGENT; CYCLIN B; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; RIBONUCLEASE; SURVIVIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CELL CYCLE; CELL CYCLE G2 PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC CODE; GERMINAL CENTER; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVIEW; RIBONUCLEASE PROTECTION ASSAY; SURVIVAL RATE; TUMOR CELL;

EID: 85014269563     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402427     Document Type: Review

References (51)

1. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
2. Diffuse large-cell lymphoma
3. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma
4. Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: Regulators of growth fraction and programmed cell death
5. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
6. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: Prognostic significance of E2F-1 and p16INK4A
7. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
8. Genomic-scale gene expression profiling of normal and malignant cells
9. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
10. Cell proliferation and apoptosis
11. Cancer. Tuning in on death programs
12. Apoptosis in cancer
13. p53 status and the efficacy of cancer therapy in vivo
14. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
15. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
16. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
17. A matter of life and cell death
18. Deregulation of cell survival in lymphomagenesis
19. t(14;18), a journey to eternity
20. p53 regulates a G2 checkpoint through cyclin B1
21. The G2 checkpoint is maintained by redundant pathways
22. Cooperative effects of genes controlling the G2/M checkpoint
23. BCL-2 gene family and the regulation of programmed cell death
24. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 Proteases)
25. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells
26. The most unkindest cut of all: On the multiple roles of mammalian caspases
27. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
28. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
29. Control of apoptosis and mitotic spindle checkpoint by survivin
30. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death
31. Human survivin is a kinetochore-associated passenger protein
32. Pathology and genetics of tumors of haematopoietic and lymphoid tissues
33. Immunologic characterization of human malignant lymphomas
34. Updated Kiel classification for lymphomas
35. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
36. Synthesis of RNA probes by in vitro transcription of double-stranded DNA templates by bacteriophage DNA-dependent RNA polymerases
37. Effect of granulocyte-colony stimulating factor (G-CSF) mobilisation on phenotypical and functional properties of immune cells
38. The BCL-6 proto-oncogene controls germinal center formation and Th2-type inflammation
39. Control of inflammation, cytokine expression, and germinal center formation by BCL-6
40. CD10 and BCL-6 expression in paraffin section of normal lymphoid tissue and B-cell lymphomas
41. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
42. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
43. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group Trial
44. Involvement of wildtype p53 in pre-B-cell differentiation in vitro
45. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: Relationship to cyclin D1
46. Physical interaction of the retinoblastoma protein with the human D cyclins
47. Dissecting the pathways to death
48. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
49. Survivin promotes cell proliferation in human hepatocellular carcinoma
50. cdc2 phosphorylation of survivin
51. Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 promoter